Enliven Therapeutics, Inc.
ELVN
$27.25
-$0.54-1.94%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 42.17% | 27.48% | 38.65% | 48.52% | 57.93% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 14.45% | 13.30% | 20.30% | 23.61% | 31.30% |
| Operating Income | -14.45% | -13.30% | -20.30% | -23.61% | -31.30% |
| Income Before Tax | -16.78% | -14.39% | -21.33% | -18.84% | -24.04% |
| Income Tax Expenses | -- | -100.00% | -100.00% | -- | -- |
| Earnings from Continuing Operations | -16.48% | -14.07% | -20.99% | -19.14% | -24.36% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -16.48% | -14.07% | -20.99% | -19.14% | -24.36% |
| EBIT | -14.45% | -13.30% | -20.30% | -23.61% | -31.30% |
| EBITDA | -14.54% | -13.36% | -20.36% | -23.69% | -31.39% |
| EPS Basic | 2.24% | 3.18% | -3.52% | -0.19% | 12.85% |
| Normalized Basic EPS | 2.93% | 2.24% | -6.45% | -6.12% | 8.24% |
| EPS Diluted | 2.24% | 3.18% | -3.52% | -0.19% | 12.85% |
| Normalized Diluted EPS | 2.93% | 2.24% | -6.45% | -6.12% | 8.24% |
| Average Basic Shares Outstanding | 20.30% | 19.27% | 16.25% | 18.82% | 32.91% |
| Average Diluted Shares Outstanding | 20.30% | 19.27% | 16.25% | 18.82% | 32.91% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |